Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Aspiration Clear all
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

NCT03622112
View directory record Official record
Conditions
Asthma
Interventions
AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
21
States / cities
Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 27, 2026, 7:05 AM EDT
Terminated Phase 1 Interventional

The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children

NCT03040596
View directory record Official record
Conditions
Vocal Fold Nodules
Interventions
Fluticasone propionate, Standard voice therapy
Drug · Behavioral
Lead sponsor
Joseph Dohar, MD
Other
Eligibility
4 Years to 11 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 27, 2026, 7:05 AM EDT
Not yet recruiting Not applicable Interventional

Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort

NCT06078527
View directory record Official record
Conditions
Presbylarynx, Aspiration, Spasmodic Dysphonia, Globus Pharyngeus, Larynx Paralysis, Laryngeal Disease, Vocal Cord Paralysis, Iatrogenic Injury, Sensory Neuropathy
Interventions
Cheung-Bearelly Aesthesiometer, Transnasal Laryngoscopy, Questionnaires
Device · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 27, 2026, 7:05 AM EDT
Withdrawn Phase 2 Interventional

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

NCT00323024
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
NX1011
Drug
Lead sponsor
NITROX, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2007 · Synced Sep 27, 2026, 7:05 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446
View directory record Official record
Conditions
Refractory or Unexplained Chronic Cough
Interventions
NOC-110, Placebo
Drug · Other
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
68
States / cities
Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 27, 2026, 7:05 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Impact of Breathing Interventions on Stress Markers

NCT05825846
View directory record Official record
Conditions
Physiological Stress
Interventions
Virtual- reality active shooter drill
Device
Lead sponsor
Texas State University
Other
Eligibility
18 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Marcos, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 27, 2026, 7:05 AM EDT
Terminated No phase listed Observational

Prone Patient Positioning in Reducing Tumor Motion and Improving Breathing Reproduction in Patients With Lung Cancer Undergoing Radiation Therapy

NCT01851161
View directory record Official record
Conditions
Lung Cancer
Interventions
computed tomography, 4-dimensional computed tomography, radiation therapy
Procedure · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Total Intravenous Anesthesia in Sinus Surgery

NCT02578862
View directory record Official record
Conditions
Advanced Chronic Rhinosinusitis
Interventions
Propofol, Sevoflurane
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Early Phase 1 Interventional

Inhaled Iloprost in Mild Asthma

NCT01209533
View directory record Official record
Conditions
Asthma
Interventions
Iloprost
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Sep 27, 2026, 7:05 AM EDT
Terminated No phase listed Observational

Effects of Oxygen on Lung Tissue During Anesthesia

NCT00715338
View directory record Official record
Conditions
Lung Injury, Acute
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients

NCT02932332
View directory record Official record
Conditions
Cancer
Interventions
High-flow Oxygen, Low-flow Oxygen, High-flow Air, Low-flow Air
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Aerosol Inhalation Treatment for Dyspnea

NCT01440764
View directory record Official record
Conditions
Healthy, Dyspnea
Interventions
Furosemide, Saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02630316
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
96
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

NCT03727802
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
TRK-250, Placebo
Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 27, 2026, 7:05 AM EDT
Terminated Phase 3 Interventional

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

NCT00005777
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo
Procedure · Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
5 Minutes to 10 Days
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study

NCT01571037
View directory record Official record
Conditions
End Stage Heart Disease, Right Ventricular Dysfunction
Interventions
inhaled nebulized milrinone
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2
Interventions
Technosphere® Insulin Inhalation Powder, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
82
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 27, 2026, 7:05 AM EDT
Not listed Not applicable Interventional

Inspiratory Muscle Training in COPD

NCT03438019
View directory record Official record
Conditions
COPD
Interventions
PrO2, Threshold Inspiratory Muscle Trainer
Device
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 27, 2026, 7:05 AM EDT
Not listed Phase 1Phase 2 Interventional

Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO

NCT02851472
View directory record Official record
Conditions
Anemia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
New York Medical College
Other
Eligibility
2 Weeks and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Springfield, Massachusetts • Stony Brook, New York • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 4 Interventional Results available

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

NCT03502070
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, Tobi Podhaler
Drug · Device
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Miami, Florida • Orlando, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Establishing Pressures at the EGJ During Diaphragmatic Breathing Using High-resolution Esophageal Manometry

NCT06329583
View directory record Official record
Conditions
Gastroesophageal Reflux, Dysphagia, Esophageal Motility Disorders
Interventions
diaphragmatic breathing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 27, 2026, 7:05 AM EDT
Completed Phase 1Phase 2 Interventional

Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial

NCT01242462
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Conventional Pressure Controlled SIMV, Mid-frequency Ventilation
Procedure · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 7 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 27, 2026, 7:05 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401
View directory record Official record
Conditions
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
Interventions
AP01, Placebo
Drug · Other
Lead sponsor
Avalyn Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
61
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 27, 2026, 7:05 AM EDT